甲磺酸伊马替尼治疗胃肠间质瘤64例疗效和安全性分析  

Safety and efficacy of imatinib mesylate in gastrointestinal stromal tumours:an analysis of 64 cases

作　　者：王雅杰[1] 薛春燕[1] 王宁[1] 

机构地区：[1]第二军医大学长海医院肿瘤科,上海200433

出　　处：《中国实用外科杂志》2010年第4期294-296,共3页Chinese Journal of Practical Surgery

摘　　要：目的评价甲磺酸伊马替尼治疗胃肠间质瘤的临床疗效及不良反应。方法分析第二军医大学长海医院肿瘤科2007年1月至2009年9月间64例经术后病理证实的GIST病人的临床资料。病人均给予甲磺酸伊马替尼400mg/d口服。每3个月复查CT,以明确病人病情变化情况。结果64例病人平均随访20个月。局限可切除GIST病人38例,无一例发生复发或转移;26例局部晚期/转移性GIST中完全缓解1例(3.85%),部分缓解18例(69.2%),稳定4例(15.4%),进展3例(11.5%),客观缓解率(完全缓解+部分缓解)为73.1%。1年存活率为98.4%。中位生存时间超过19个月。结论甲磺酸伊马替尼用于GIST术后辅助治疗,对预防肿瘤的复发和转移可能具有一定的作用;对于复发/转移性病人具有高的有效率和较好的安全性。Objective To investigate the efficacy and adverse effects of imatinib mesylate in gastrointestinal stromal tumors （GIST）. Methods A total of 64 patients with GIST were administered with imatinib mesylate between January 2007 and September 2009 at Department of Oncology, Changhai Hospital Attached to the Second Military Medical University.All the patients were managed at a daily dose of 400mg/d and followed up by CT every 3 months. Results Sixty-four patients were followed up for 20 months. Thirty-eight patients were performed local surgical resection and no recurrence was detected.Twenty-six advanced or metastatic GIST patients survived a median overall survival of more than 19 months and 98.4% survived 12 months. One patient （3.85%） showed complete response （CR）.Eighteen patients （69.2%） showed partial response（PR）,4 patients （15.4%） stable disease and 3 patients （11.5%） progressive disease. The overall response rate （CR ＋ PR） was 73.1%. One year survival rate was 98.4%. The median survival time was more than 19 months. Conclusion Imatinib mesylate as an extremely effective and safe therapy for majority of GIST is believed to be effective against both local and unresectable GIST and toxicity is minimal.

关 键 词：胃肠间质瘤 甲磺酸伊马替尼 

分 类 号：R6[医药卫生—外科学]